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Background: Extranodal extension (ENE) in lymph node metastases has been shown to worsen the prognosis of
papillary thyroid cancer (PTC). Despite the clinical significance of ENE, there are no stringent criteria for its
microscopic diagnosis, and its identification is subject to inter-observer variability. The objective of this study
was to determine the level of agreement among expert pathologists in the identification of ENE in PTC cases.
Methods: Eleven expert pathologists from the United States, Italy, and Canada were asked to review 61 scanned
slides of representative permanent sections of PTC specimens from Mount Sinai Beth Israel Medical Center in
New York. Each slide was evaluated for the presence of ENE. The pathologists were also asked to report the
criteria they use to identify ENE.
Results: The overall strength of agreement in identifying ENE was only fair (j= 0.35), and the proportion of
observed agreement was 0.68. The proportions of observed agreement for the identification of perinodal
structures (fat, nerve, skeletal, and thick-walled vessel involvement) ranged from 0.61 to 0.997.
Conclusions: Overall agreement for the identification of ENE is poor. The lack of agreement results from both
variation in pathologists’ identification of features and disagreement on the histologic criteria for ENE. This
lack of concordance may help explain some of the discordant information regarding prognosis in clinical studies
when this feature is identified.
Introduction
The overall prognosis for the vast majority of patientswith papillary thyroid carcinoma (PTC) is excellent.
However, the risks of recurrence and mortality are signifi-
cantly increased for those with advanced stages of disease.
Nodal involvement is one factor that influences the staging of
thyroid disease in the American Joint Committee on Cancer
(AJCC) system for tumor nodal disease and distant metastasis
(TNM) staging. A patient with PTCwho is >45 years of age is
upstaged from Stage I to III or IV if nodal metastases are
identified (patients are upstaged to Stage III if lymph node
metastases are present in level 6 of the neck and upstaged to
Stage IV if lymph node metastases are found in the lateral
compartment [levels 1–5] or the mediastinum [level 7]). In
the 2009 guidelines, the American Thyroid Association
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(ATA) proposed a three-tiered stratification system for the
risk of recurrence, with the categories of low, intermediate,
and high risk of recurrence. Patients with cervical lymph node
metastases are placed in the intermediate risk category (1).
It has long been recognized that there is a wide spectrum of
nodal characteristics in patients with PTC that ranges from
micrometastases (manifesting as single isolated, or ‘‘naked,’’
psammoma bodies, single viable tumor cells, or small clus-
ters of tumor cells) to enlarged, macroscopic nodes demon-
strating extensive extranodal extension (ENE) (2). Thus,
increasingly, studies suggest that future PTC staging systems
ought to account for various nodal characteristics, such as
size, number, location, and ENE (3–6). In 2012, Randolph
et al. published a meta-analysis that addressed the impact of
different nodal characteristics on the risk of disease recur-
rence (4). In that study, the characteristics considered most
significant included (i) whether a node is clinically evident,
(ii) the number of positive nodes, (iii) the size of the largest
node, and (iv) the presence of ENE (4).
The overall rate of ENE in patients with PTC is reported to
be between 22% and 45% (6–8). ENE is a strong and inde-
pendent predictor of disease recurrence and disease-specific
survival (6,8–10), and a predictor of distant metastases (11).
Of note, the study byRandolph et al. suggested that ENE is the
strongest prognostic factor among all lymph node parameters
(even more so than location of nodal involvement) (6).
In a recent study, it was found that 62% of patients un-
dergoing prophylactic central compartment dissections had
one or more pathologically positive nodes, and 14% of these
patients had lymph nodes that demonstrated ENE (12).
However, the exact incidence of ENE in metastatic lymph
nodes in PTC cases is difficult to estimate, since performing a
prophylactic central neck dissection in the absence of clini-
cally evident nodal disease is controversial.
Even though ENE has become an increasingly recognized
prognostic factor in PTC, it must be acknowledged that there
are no stringent criteria for its microscopic diagnosis, and
thus its identification can be subject to inter-observer vari-
ability (3). The most recent College of American Pathologists
Protocol for the Examination of Specimens From Patients
With Carcinomas of the Thyroid Gland (2014) notes the
importance of documenting the presence or absence of ENE
(13). However, histologic criteria for identifying ENE are not
defined (13).
To the authors’ knowledge, there are no reported studies
analyzing the degree of concordance among pathologists in
the assessment of ENE. This study seeks to evaluate the de-
gree of inter-observer variability in the histopathologic
identification of ENE, as well as the current criteria used by
pathologists for its identification. As the prognostic signifi-
cance of ENE is increasingly recognized and incorporated
into PTC staging systems, it is important to understand the
variability in its histopathologic identification.
Materials and Methods
This study was performed with approval by the Mount
Sinai Beth Israel Medical Center Institutional Review Board.
Eleven expert pathologists from the United States, Canada,
and Italy were asked to review 61 scanned slides of repre-
sentative permanent sections of PTC specimens from Mount
Sinai Beth Israel Medical Center in New York. Slides were
selected that were potentially controversial with respect to
the presence of ENE (determined by a senior pathologist,
B.M.W.). All slides were prepared with standard hematoxy-
lin and eosin (H&E) stain. The slides were digitally scanned
at 40· using the Aperio ScanScope AT Turbo. All 11 pa-
thologists evaluated each case.
Pathologists reviewed each slide and designated the
specimen as demonstrating ENE or having no evidence of
ENE. In addition, pathologists were asked to evaluate spe-
cifically for perinodal involvement of fat, skeletal muscle,
nerve, and thick-walled vascular structures. A survey was
used to determine the specific criteria used by each pathol-
ogist for diagnosing ENE.
The kappa coefficient was computed to assess consistency
in the pathologists’ categorization of each slide and the fea-
tures evaluated. All statistical analyses were done with R
statistical package v3.1.1 (R Development Core Team,
Vienna, Austria).
Results
Overall, the proportion of observed agreement for the
histologic diagnosis of ENE was 0.68 and produced a kappa
coefficient of 0.35, indicating that the strength of agreement
was fair (Table 1). The proportion of observed agreement for
the identification of perinodal structures was lowest for
perinodal fat involvement (0.61), and highest for perinodal
nerve and muscle involvement (0.98 and 0.997).
All of the surveyed pathologists reported that they use
perinodal fat involvement as a histologic criterion for diag-
nosing ENE (Table 2). Skeletal muscle, nerve, and thick-
walled vessel involvement are also taken into consideration
to varying degrees. Seven pathologists reported use of all four
Table 1. Kappa Coefficient for Inter-Pathologist Agreement of Presence
of ENE and Involvement of Perinodal Structures
Kappa coefficient
Strength of
agreementa
Proportion of observed
agreement
Presence of ENE 0.35 Fair 0.68
Perinodal fat involvement 0.2 Slight/fair 0.61
Perinodal nerve involvement 0.09 Slight 0.98
Perinodal skeletal muscle involvement 0 Slight 0.997
Perinodal thick-walled vessel involvement 0.02 Slight 0.87
aKappa agreement: <0, less than chance agreement; 0.00–0.20, slight agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate
agreement; 0.61–0.80, substantial agreement; 0.81–0.99, almost perfect agreement.
ENE, extranodal extension.
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perinodal structures as part of the diagnostic criteria for ENE,
and the remaining four pathologists use between one and
three structures. The most common additional criterion used
by pathologists to diagnose ENE is ‘‘tumor beyond nodal
capsule,’’ which was reported by 8/11 of the pathologists in
this study. Other criteria utilized by pathologists include
‘‘fibrosis with desmoplasia outside node,’’ ‘‘extrinsic exten-
sion into vessels, not tumor emboli,’’ and ‘‘desmoplastic
stromal reaction outside node.’’
Discussion
As indicated by a kappa coefficient of 0.35, the overall
strength of inter-pathologist agreement among 11 experts for
the histologic diagnosis of ENE in PTC is only fair. The low
degree of concordance indicates that the pathologic diagnosis
of ENE can be inconsistent and prone to subjectivity.
Raters indicated that perinodal nerve, skeletal muscle, and
thick-walled vessel involvement were not observed for the
vast majority of slides. While the kappa coefficients are low
for the identification of these features, this is due to the low
incidences of positive identification. Thus, for this analysis,
the proportions of observed agreement for perinodal nerve,
skeletal muscle, and thick-walled vessel involvement, which
were 0.98, 0.997, and 0.87 respectively, are the more accurate
representation of inter-pathologist agreement.
The concordance for identifying individual structure in-
volvement was higher than concordance for the identification
of ENE. While the proportion of observed agreement for the
identification of ENE was 0.68, the proportion of observed
agreement for the identification of perinodal fat, nerve,
skeletal muscle, and thick-walled vessel involvement were
0.61, 0.98, 0.997, and 0.87, respectively. These results indi-
cate that a disagreement over the proper criteria for identi-
fying ENE is what leads to the poor inter-pathologist
concordance in the overall diagnosis of ENE. These findings
suggest that the standardization of the histologic criteria for
ENE through establishment of consensus pathologic guide-
lines should improve uniformity in the diagnosis of ENE.
There are several potential limitations of this study. First,
the sample size included only 11 pathologists. Only senior
pathologists from various medical centers in the United
States, Canada, and Italy considered to be experts in thyroid
pathology were invited to partake in the study. This naturally
biases the group toward pathologists who are more experi-
enced with ENE and PTC, and who would not necessarily be
representative of all pathologists who might review nodal
specimens from patients with PTC. In fact, one might surmise
that the degree of concordance for less experienced pathol-
ogists would be less than that determined in this study. A
second study designed to engage pathologists in community
hospitals would help to clarify this point. The second limi-
tation is that the pathologists were only reviewing a single
imaged slice from each specimen. In practice, pathologists
often review multiple sections and/or levels. Since there is no
standardized protocol for the extent to which a lymph node
should be sectioned, it is likely that the presence of ENE is
under-reported by virtue of the fact that more extensive
sectioning may identify areas of extranodal spread.
The presence of ENE is a significant prognostic factor in
thyroid cancer, is an important component in the assignment
of risk of recurrent disease, and may be taken into account in
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the decision to administer radioactive iodine therapy. Thus,
clinicians must understand the lack of concordance in path-
ologic diagnosis of ENE. The lack of concordance in iden-
tifying ENE could also greatly impact the interpretation of
clinical studies that assess the influence of ENE on disease
prognosis.
In conclusion, this study evaluates inter-observer concor-
dance in the histologic identification of ENE, a finding that is
increasingly considered important in the staging and treat-
ment of PTC. Overall agreement on the identification of ENE
is poor, likely caused by disagreement in the histologic cri-
teria used for the diagnosis of ENE. The lack of concordance
in the diagnosis of ENE has potential implications for both
disease prognosis and patient care, and it needs to be recog-
nized by clinicians treating PTC patients in order to allow
appropriate assessment of studies that include ENE as a
prognostic variable. Clinicians should be cognizant of this
variability when reviewing the pathology reports on their
patients.
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